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AbstrACt 
Objectives Evidence to support initiation of 
pharmacological treatment in patients with uncomplicated 
(low risk) mild hypertension is inconclusive. As such, 
clinical guidelines are contradictory and healthcare 
policy has changed regularly. The aim of this study was 
to determine the incidence of lifestyle advice and drug 
therapy in this population and whether secular trends were 
associated with policy changes.
Design Longitudinal cohort study.
setting Primary care practices contributing to the Clinical 
Practice Research Datalink in England.
Participants Data were extracted from the linked 
electronic health records of patients aged 18–74 years, 
with stage 1 hypertension (blood pressure between 140/90 
and 159/99 mm Hg), no cardiovascular disease (CVD) risk 
factors and no treatment, from 1998 to 2015. Patients 
exited if follow-up records became unavailable, they 
progressed to stage 2 hypertension, developed a CVD risk 
factor or received lifestyle advice/treatment.
Primary outcome measures The association between 
policy changes and incidence of lifestyle advice or 
treatment, examined using an interrupted time-series 
analysis.
results A total of 108 843 patients were defined as 
having uncomplicated mild hypertension (mean age 
51.9±12.9 years, 60.0% female). Patientsspent a median 
2.6 years (IQR 0.9–5.5) in the study, after which 12.2% 
(95% CI 12.0% to 12.4%) were given lifestyle advice, 
29.9% (95% CI 29.7% to 30.2%) were prescribed 
medication and 19.4% (95% CI 19.2% to 19.6%) were 
given both. The introduction of the quality outcomes 
framework (QOF) and subsequent changes to QOF 
indicators were followed by significant increases in the 
incidence of lifestyle advice. Treatment prescriptions 
decreased slightly over time, but were not associated with 
policy changes.
Conclusions Despite secular trends that accord with UK 
guidance, many patients are still prescribed treatment for 
mild hypertension. Adequately powered studies are needed 
to determine if this is appropriate.
IntrODuCtIOn
High blood pressure (hypertension) is a key 
risk factor for the development of cardio-
vascular disease,1 a major cause of mortality 
worldwide.2 The threshold for hypertension is 
a sustained blood pressure >140/90 mm Hg, 
and many guidelines recommend pharma-
cological treatment is initiated immediately 
at this level, or after a period of unsuccessful 
lifestyle modification, regardless of the under-
lying risk of cardiovascular disease.3–8 These 
recommendations are considered controver-
sial, particularly with regard to treatment of 
uncomplicated (ie, low cardiovascular disease 
strengths and limitations of this study
 ► This study examined electronic health records from 
a large, nationally representative sample of the UK 
population.
 ► Analyses were undertaken according to a prespec-
ified protocol which was reviewed and approved by 
an independent scientific advisory committee.
 ► Mild hypertension was defined consistently ac-
cording to blood pressure readings, meaning that 
those with a diagnostic code for hypertension but 
no associated blood pressure values may have been 
excluded.
 ► Low-risk patients were defined according to indi-
vidual risk factors, rather than an established risk 
calculator due to large amounts of missing data (eg, 
for cholesterol, body mass index), potentially un-
derestimating the number of truly low-risk patients 
available for analysis.
 ► The incidence of lifestyle advice was defined ac-
cording to clinical codes but it was not possible to 
identify patients given lifestyle advice where it was 
either not coded or where it was only recorded in the 
free text consultation notes.
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risk) people with ‘mild’ hypertension (ie, sustained blood 
pressure between 140/90 and 159/99 mm Hg (stage 
1)).9–14 
There is little evidence to support initiation of pharma-
cological treatment in patients with uncomplicated mild 
hypertension. A Cochrane review15 of trials in this popu-
lation found no reduction in mortality or cardiovascular 
events with treatment, but was underpowered to detect 
significant differences.10 15 More recent studies16 17 have 
shown benefit with treatment in patients with mild hyper-
tension. However, these included a significant proportion 
of patients with diabetes or at least one other cardiovas-
cular risk factor and therefore participants would not 
be considered ‘uncomplicated’ under current clinical 
guidelines.18
Clinical guidelines often make recommendations 
based on ‘expert opinion’ where evidence is lacking or 
inconsistent. Such guidelines are predictably contradic-
tory, with those in the UK promoting lifestyle modifica-
tion in low-risk patients18while guidelines from Europe6 
and the USA4 7 8 encourage prescription of drug therapy. 
Recently, an international expert consultation recom-
mended early initiation of blood pressure-lowering 
treatment with lifestyle advice reserved only for patients 
with grade 1 isolated hypertension.14 Against this back-
ground, a number of guideline and policy changes have 
occurred in the UK over the past 10 years which may 
have affected general practitioner’s (GP’s) treatment 
decisions. In particular, the introduction of a nation-
wide cardiovascular risk screening programme (the 
National Health Service (NHS) health check) in 2009,19 
and pay-for-performance indicators (the quality and 
outcomes framework (QOF)), which promoted both 
more lifestyle advice and stricter treatment targets in 
this population.20
The aim of this study was to use routine patient 
records from the Clinical Practice Research Datalink 
(CPRD)21 to establish the proportion of patients given 
lifestyle advice and/or pharmacological treatment for 
uncomplicated mild hypertension in primary care and 
the association of policy with changes to these propor-
tions over time.
MethODs
Design
This was a longitudinal cohort study in conducted in 
Primary Care from 1998 to 2015 using data from the 
CPRD, a database of electronic health records from 
England.21 The incidence of lifestyle advice and treatment 
prescriptions was estimated by month, adjusted for age 
and sex. The association of guideline and policy changes 
was examined using an interrupted time-series analysis 
with introduction of the NHS health check19 and changes 
in QOF indicators20 defined as prespecified break points. 
The CPRD population has been shown previously to 
approximate to the UK population.21
study population
Individual patient data were extracted from the medical 
records of all patients registered at general practices 
contributing to the CPRD in England. Patients were 
entered into the study on the date of the third consecutive 
blood pressure reading between 140/90 and 159/99 mm 
Hg occurring after the study start date 1 January 1998. 
The start date was chosen because it represents the date 
from which all relevant data linkages were first available. 
Patients exited the study if they had three consecutive 
blood pressure readings >160/100 mm Hg (ie, progressed 
to stage 2 hypertension), developed a risk factor for 
cardiovascular disease, received lifestyle advice or treat-
ment or follow-up records became unavailable (patient or 
practice left the CPRD) (table 1). The last day of follow-up 
for those remaining in the study was 30 September 2015 
(last day of follow-up in linked data).
Outcomes
The primary outcome of this study was evidence that 
lifestyle advice and/or pharmacological treatment had 
been given during follow-up. Lifestyle advice was defined 
as Read code for any lifestyle advice relating to smoking, 
alcohol, diet, hypertension, physical activity, weight, 
oral health or lipid disorders (see online supplemen-
tary appendix etable 1). Pharmacological treatment was 
defined as a coded prescription of an ACE inhibitor, 
angiotensin II receptor blocker, calcium channel blocker, 
thiazide or thiazide-like diuretic, beta-blocker, alpha-
blocker or any other antihypertensive listed in the British 
National Formulary (see online supplementary appendix 
etable 2).
Covariates
Data relating to baseline patient characteristics (age, sex, 
ethnicity, (practice level) deprivation), lifestyle factors 
(smoking status (never, current, ex-smoker), alcohol 
consumption (units per week), and body mass index 
(BMI)), pretreatment blood pressure readings (in the 
preceding 12 months), related comorbidities (rheuma-
toid arthritis, hypercholesterolaemia (Read code for 
hypercholesterolaemia or most recent total cholesterol 
value >7.5 mmol/L)) and all prescribed statin/anti-
platelet medications were extracted from the CPRD data-
base and used to define the study population.
Quantitative data
Ethnicity was classified into white, black, South Asian, 
mixed race, other and unknown groups. The Index of 
Multiple Deprivation (IMD) was provided as quintiles of 
deprivation in England, with the highest quintile indi-
cating the highest level of deprivation. Smoking status 
was defined as never, previous or current smoker. Those 
with unknown smoking status were assumed to have never 
smoked. Where there was no record of blood pressure 
lowering, statin or antiplatelet treatment, it was assumed 
that patients were not prescribed treatment.
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Only patients with records deemed ‘acceptable for 
research purposes’ by CPRD were included in the anal-
ysis, and hence age and sex information was complete. 
Where there was no record of alcohol consumption, rheu-
matoid arthritis or hypercholesterolaemia, patients were 
assumed to be non-drinkers and have no history of these 
conditions. Where there was no record of blood pressure 
lowering, statin or antiplatelet treatment, it was assumed 
that patients were not exposed to any treatment. A total 
of 91 patients (0.001%) were missing IMD data and were 
excluded. To enable calculation of a cardiovascular risk 
score for sensitivity analyses, missing values for choles-
terol and BMI were simulated once, assuming a normal 
distribution, and using means and SD in each age–sex 
strata from the 2011 Health Survey for England.22
sample size
As a descriptive study, no formal sample size calculation 
was required. All patients from the CPRD fulfilling the 
eligibility criteria were included.
statistical analysis
Descriptive statistics were used to describe the study 
population and estimate the proportion of patients being 
offered lifestyle advice or therapy (or both) following a 
diagnosis of uncomplicated mild hypertension.
The impact of the introduction of the NHS health 
check programme in April 200919 (month 111) and 
changes to QOF indicators (April 2009 and 2013 (month 
159))20 (see table 2) on lifestyle advice and treatment 
prescription rates were examined using an interrupted 
time-series analysis. A 2-year run-in phase (1998–1999) 
was used, where patients could enter and leave the 
cohort, but incidence rates were not estimated. This was 
to ensure the cohort accumulated sufficient numbers of 
patients to enable accurate estimates of monthly inci-
dence in the subsequent time period after the analysis 
start date (1 January 2000). The slope of the monthly 
rate of lifestyle advice and treatment over time was esti-
mated (189 months in total), before policy change was 
introduced (months 111 and 159), along with the differ-
ence in the starting level (intercept) and slope of this rate 
in the period after each policy change was introduced, 
using ordinary least-squares regression with Newey-West 
corrected SEs (which account for autocorrelation). Esti-
mates were adjusted for age and sex and all slopes are 
presented as incidence per year. P values indicate signif-
icance of the difference between the slope/intercept in 
the post-policy period, compared with estimates from the 
pre-policy period.
As a post hoc analysis, the impact of the introduction 
of the QOF in 200423 (month 59) was explored as an 
additional breakpoint in the interrupted time-series anal-
ysis. Sensitivity analyses explored the impact of excluding 
those deemed to be at high risk due to (1) high cardiovas-
cular risk score documented in the primary care physician 
notes and (2) high cardiovascular risk score documented 
in the notes or estimated using the QRISK2 algorithm24 
and available risk factor data.
Data access and cleaning methods
SS had access to the entire CPRD database from which 
eligible patients were identified and all data extracted. 
Table 1 Study entry and exit criteria applied to potential participant records used in the study
Study entry criteria Study exit (first to occur)
Date of the third consecutive blood pressure reading between 
140/90 and 159/99 mm Hg (within 12 months of each other)
Last date at which the most recent linked data are available 
from the CPRD (study end date, September 2015)
Aged between 18 and 74 years Date of third consecutive blood pressure reading 
>160/100 mm Hg (within 12 months of each other) 
(progression to stage 2 hypertension)
Linked general practice, Hospital Episodes Statistics and Office 
for National Statistics mortality records
Date of first record of a cardiovascular risk factor (left 
ventricular hypertrophy, atrial fibrillation, diabetes or chronic 
kidney disease or family history of premature heart disease) 
or high cardiovascular risk score (>20%)
Registered to a CPRD practice classified as ‘up-to-standard’ Date of death
Classified as a CPRD ‘acceptable patient’ Date of the most recent data upload from the practice to 
which a given patient is registered
No Read code for previous cardiovascular disease (stroke, 
myocardial infarction, angina, coronary heart disease, peripheral 
vascular disease, heart failure)
Date at which a given patient transfers out of a registered 
CPRD practice
No Read code for cardiovascular risk factor (left ventricular 
hypertrophy, atrial fibrillation, diabetes or chronic kidney disease 
or family history of premature heart disease)
Date of first coded lifestyle advice given after study entry 
(lifestyle advice analysis only)
No record of any blood pressure lowering medication prescription 
in the 12 months prior to the third consecutive blood pressure 
reading between 140/90 and 159/99 mm Hg
Date of first prescribed antihypertensive treatment given 
after study entry (treatment analysis only)
CPRD, Clinical Practice Research Datalink.
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Where multiple blood pressure values appeared in the 
record on any one day, the lowest value was selected. 
Treatments/diagnoses of conditions were determined 
from the presence of at least one coded prescription/
diagnostic code, respectively. Baseline data were extracted 
from within each patient’s up to standard registration 
period and were drawn from the latest available record 
prior to study entry. Values deemed a priori to be clin-
ically implausible were excluded (eg, weight values of 
<20 kg and >200 kg). Where there was evidence of prior 
smoking but the most recent smoking status recorded 
indicated no smoking, this was corrected by classifying 
patients as former smokers.
Measures taken to reduce bias
To reduce the possibility of selection bias, all patients 
fulfilling the eligibility criteria for the study were included. 
Mild hypertension was defined according to measured 
blood pressure values rather than diagnostic codes, to 
reduce the potential for reporting bias, particularly in the 
pre-QOF era when coding was less standardised. For the 
primary analysis, breakpoints for the interrupted time-se-
ries analysis were prespecified based on policy changes 
thought likely to influence the giving of lifestyle advice 
and treatment, rather than trends observed in the data.
Data linkage
Data linkage to the Office for National Statistics (ONS) 
mortality register was used to define patient mortality 
(patient exit from the study). Linkages to Basic Inpatient 
Hospital Episode Statistics (HES) were used in conjunc-
tion with CPRD records to define patient eligibility for the 
study (eg, previous stroke), and define patient ethnicity 
(where unavailable in primary care records). A linkage to 
the IMD was required to acquire practice level indices of 
multiple deprivation.
Patient involvement
Patients were not involved in the development or design 
of this study.
Approval
The present study protocol (16_008R) was approved by 
this committee in March 2016, prior to obtaining the 
data cut (protocol given in the online supplementary 
appendix). A project summary was published on the 
CPRD website (https://www. cprd. com/ isac).
All data cleaning and analyses were conducted using 
STATA V.13.1 and 14.2 (MP parallel edition, StataCorp). 
Results are presented as means, medians or proportions, 
with SD, IQR or 95% CIs, unless otherwise stated.
results
Prevalence of lifestyle advice and treatment
Of the 7 416 968 individuals aged 18–74 years registered at 
linked, up-to-standard practices within the CPRD during 
the study period, a total of 108 843 patients (1.46%, 95% CI 
1.45% to 1.47%) from 694 practices (333±192 patients per 
practice) met the criteria for having uncomplicated mild 
hypertension during the study period (figure 1). Included 
patients had a mean age of 51.9±12.9 years, 60.0% (95% 
CI 59.7% to 60.3%) were female and mean blood pres-
sure (across three visits) was 144.3±5.9/87.3±5.8 mm Hg 
(table 3). Patients spent a median time of 2.6 years in the 
study (IQR 0.9–5.5) and exited the cohort due to devel-
opment of stage 2 hypertension (6269 patients (5.8%)), 
a cardiovascular risk factors or score >20% (3496 patients 
(5.0%)), advice being given (18 647 patients (17.1%)), 
treatment prescribed (35 305 patients (32.4%)), end of 
study follow-up (38 515 patients (35.4%)) or a combina-
tion of reasons (4656 patients (4.3%)). During the study 
period, a total of 13 269 (12.2%, 95% CI 12.0% to 12.4%) 
were given lifestyle advice alone, 32 578 (29.9%, 95% CI 
29.7% to 30.2%) were only prescribed an antihypertensive 
and 21 128 (19.4%, 95% CI 19.2% to 19.6%) were given 
lifestyle advice and prescribed treatment (table 3). The 
most common type of lifestyle advice given was related to 
smoking (20.6%, 95% CI 20.4% to 20.9%; online supple-
mentary appendix etable 3).
Interrupted time-series analysis
In the pre-NHS health check period from January 2000 to 
April 2009, the proportion of patients receiving lifestyle 
advice increased from zero by 0.04% per year (95% CI 
0.04% to 0.05%) (figure 2A). The introduction of the 
NHS health check and new QOF indicators in April 
2009 was associated with a significant drop in lifestyle 
advice being given (p<0.001), but thereafter it increased 
by 0.19% per year (95% CI 0.15% to 0.23%). Following 
changes to QOF indicators in April 2013, the incidence 
of lifestyle advice decreased by −0.27% per year (95% CI 
−0.35% to −0.19%).
Treatment prescriptions were given to approximately 
1.29% (95% CI 1.23% to 1.34%) of patients with uncom-
plicated mild hypertension in the first month of the study, 
but the incidence then decreased by −0.05% (95% CI 
−0.06% to −0.05%) per year in the pre-policy period until 
2009 (figure 2B). Neither the introduction of the NHS 
health check, nor changes to QOF indicators significantly 
affected the incidence of treatment prescriptions which 
decreased by −0.03% per year and then −0.10% per year 
in the post NHS health check and QOF indicator change 
periods, respectively (figure 2B).
Post hoc analysis
The introduction of the QOF and clinical guidelines for 
the management of hypertension in 2004 was associated 
with a step-change increase in the incidence of lifestyle 
advice of 0.15% (95% CI 0.05% to 0.26%; p=0.006) 
(figure 3A). Subsequently, there was a small but signifi-
cant decrease in the incidence of lifestyle advice (−0.05% 
per year, 95% CI −0.07% to −0.04%). The NHS health 
check and new QOF indicators in 2009 were no longer 
associated with a significant drop in lifestyle advice when 
the introduction of the QOF (in 2004) was included as 
a cut-point in the post hoc analysis (p=0.07). No policy 
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or guideline changes were associated with significant 
changes in the incidence of treatment prescriptions 
for uncomplicated mild hypertension during the study 
period in the post hoc analysis (figure 3B). Exclusion of 
high-risk patients (using either definition) in the sensi-
tivity analysis had no impact on the incidence of lifestyle 
advice or treatment prescription.
DIsCussIOn
The present study examined a large database of elec-
tronic health records to establish the incidence of 
guideline recommended lifestyle advice and non-guide-
line recommended treatment for uncomplicated mild 
hypertension in primary care. Across the study period, 
approximately one-third of patients received lifestyle 
advice while half were prescribed antihypertensive treat-
ment. The introduction of pay-for-performance indica-
tors in 2004,23 and more recently a cardiovascular risk 
screening programme,19 was associated with an increase 
in the proportion of patients documented as having been 
offered lifestyle advice, suggesting a more guideline based 
approach to the management of uncomplicated mild 
hypertension. However, there remains an appreciable 
proportion offered pharmacological treatment and this 
seems to be unaffected by changes to guidelines and 
policy.
strengths and limitations
This study examined electronic health records from a 
large, nationally representative sample of the UK popu-
lation.21 Participating practices included those which 
adhere to data quality standards set out by the CPRD to 
ensure accuracy of data studied. Analyses were undertaken 
according to a prespecified protocol (see online supple-
mentary appendix) which was reviewed and approved 
by an independent scientific advisory committee, mini-
mising the possibility of reporting bias and data mining.
In an attempt to define mild hypertension consistently 
across the population, it is possible that some patients 
with a diagnostic code for hypertension but no associ-
ated blood pressure values may have been excluded. 
The focus of this study was on ‘uncomplicated’ low-risk 
patients, but for pragmatic reasons, no attempt was made 
in the primary analysis to exclude those with a high risk 
of cardiovascular disease according to an established 
risk calculator24 25 due to large amounts of missing data 
(eg, for cholesterol, BMI). Patients did exit the cohort if 
Figure 1 Flow diagram showing exclusion of patient records and definition of the final cohort. BP, blood pressure; CPRD, 
Clinical Practice Research Datalink; HES, Hospital Episode Statistics; ONS, Office for National Statistics. 
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they had a coded high cardiovascular disease risk score 
during follow-up. While it is possible that some high-risk 
patients may have been included in the study cohort 
initially, sensitivity analysis excluding patients with known 
high-risk scores and those with a high estimated QRISK2 
score24 did not affect the study results.
The incidence of lifestyle advice was defined according 
to clinical codes related to the giving of lifestyle advice 
which might be of relevance to the management of 
hypertension and cardiovascular disease risk (see online 
supplementary appendix etable 1). It was not possible to 
identify patients given lifestyle advice where it was either 
not coded or where it was only recorded in the free-text 
consultation notes. The trend of increasing lifestyle advice 
coinciding with the introduction of the QOF suggests that 
it may have been under-recorded, particularly in the early 
observational period.
Previous literature
To our knowledge, this is the first study to determine the 
incidence of lifestyle advice and treatment in patients with 
uncomplicated mild hypertension. Previous studies26–30 
have focused on the prevalence of hypertension (defined 
as a blood pressure >140/90 mm Hg) and whether or 
not patients are treated and controlled, without making 
the important distinction between hypertensive patients 
where treatment is appropriate and those where it is not, 
at least according to national guidelines.18 These surveys 
estimate the prevalence of hypertension across the world 
at between 20% and 45% with estimates of treatment and 
control ranging from 55%–81% and 30%–59%, respec-
tively.29 Our data suggest that in uncomplicated mild 
hypertension treatment rates are slightly lower (49% 
across the study period), perhaps reflecting uncertainty 
around its efficacy in this population.
Figure 2 Primary analysis: incidence of lifestyle advice and treatment by month. (A) Lifestyle advice; (B) treatment Incidence 
estimates adjusted for age and sex. NHS, National Health Service; QOF, quality and outcomes framework.
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We found a trend towards increased recording of life-
style advice over time, particularly following the intro-
duction of the QOF in 2004,23 the NHS health check19 
and changes in QOF indicators in 2009. Previous studies 
examining the impact of the NHS health check have 
found no effect on the estimated prevalence of hyperten-
sion,31 but in those screened, referrals to specialist clinics 
and programmes for lifestyle advice increased sixfold.32 
The apparent association between incidence of lifestyle 
advice and changes in QOF indicators is in contrast to 
previous studies which have suggested that pay-for-perfor-
mance in the UK has not affected the quality of care for 
hypertension.33While previous data have indicated that 
equivalent quality care remains, even after an indicator 
has been removed,34 the present data suggest the oppo-
site, with the incidence of recording of lifestyle advice 
decreasing after the indicator encouraging this was 
removed in 2014.35
The incidence of treatment prescriptions slightly 
decreased over time during the study with the largest 
reduction observed in the last study period (post 
2013), perhaps due to more accurate blood pressure 
measurement and targeting of treatment brought 
about by new National Institute for Health and 
Care Excellence guidelines and the introduction of 
out-of-office blood pressure measurement for diag-
nosis in 2011.18 The overall decrease in treatment 
might suggest a change in GP treatment practice over 
the past 15 years. However, it is also possible that GP 
treatment practice has remained constant over time, 
and the number of hypertensive patients being diag-
nosed and perceived as low risk has increased, as 
evidenced by the increasing prevalence of hyperten-
sion reported annually in the QOF over the past 10 
years (from 12.5% to 13.8%).
Figure 3 Post hoc analysis: incidence of lifestyle advice and treatment by month. (A) Lifestyle advice; (B) treatment Incidence 
estimates adjusted for age and sex. NHS, National Health Service; QOF, quality and outcomes framework.
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Implications for clinical practice
The peak in prevalence of lifestyle advice coinciding with 
the inclusion of QOF indicators encouraging advice for 
physical activity, smoking cessation and diet in 2013,20 
suggests that GPs were following pay-for-performance 
indicators closely. One explanation might be the content 
of QOF templates on GP computer systems, which are 
changed depending on the indicators included in the 
QOF and are likely to have encouraged better coding of 
lifestyle advice during a GP consultation. The choice of 
pay-for-performance indicators to include and exclude 
in the QOF should therefore be considered carefully, 
ensuring that such indicators reflect evidence-based prac-
tice and optimal patient care.
One could argue that the evidence for giving life-
style advice in uncomplicated mild hypertension is as 
inconclusive as the evidence for pharmacological inter-
ventions, with many trials having short follow-up and 
exhibiting risk of bias18 36 such as inadequate randomi-
sation and allocation concealment,36 lack of blinding37 
and incomplete outcome data.38 In addition, there are no 
trials of the impact of lifestyle advice on ‘hard outcomes’ 
such as cardiovascular disease and mortality18 and the 
quality of evidence of an association from observational 
studies is generally low.39 However, lifestyle advice can 
potentially be given at lost cost within a patient consulta-
tion, and while overall reductions in blood pressure may 
be modest,36–38 some patients may wish to change their 
lifestyle in an effort to delay or prevent embarking on a 
formal treatment regimen.36
COnClusIOns
The present study shows that the introduction of 
pay-for-performance indicators and a cardiovascular 
risk screening programme have been associated with 
increased guideline recommended lifestyle advice being 
offered to patients with uncomplicated mild hyper-
tension, although the overall prevalence remains rela-
tively low. However, nearly half of the patients go on 
to be prescribed treatment, despite a lack of evidence 
suggesting benefit. This may be explained by a lack of 
clear evidence to guide treatment decisions. Adequately 
powered studies, perhaps using routine clinical data at 
scale, are required to accurately define the relationship 
between treatment and cardiovascular disease and death 
in patients with uncomplicated mild hypertension.
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